New drug duo aims to spare bladders in aggressive cancer
NCT ID NCT07151560
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 25 times
Summary
This study tests whether a combination of two drugs (disitamab vedotin and toripalimab) can help people with a certain type of bladder cancer (HER2-positive, muscle-invasive) avoid bladder removal. About 60 adults will receive the treatment and be followed for one year to see if their cancer stays away while keeping their bladder. The goal is to offer a less drastic option than surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROLOGY are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.